HALO vs. BIIB, UTHR, INCY, EXEL, NBIX, BMRN, EXAS, RGEN, MDGL, and IONS
Should you be buying Halozyme Therapeutics stock or one of its competitors? The main competitors of Halozyme Therapeutics include Biogen (BIIB), United Therapeutics (UTHR), Incyte (INCY), Exelixis (EXEL), Neurocrine Biosciences (NBIX), BioMarin Pharmaceutical (BMRN), Exact Sciences (EXAS), Repligen (RGEN), Madrigal Pharmaceuticals (MDGL), and Ionis Pharmaceuticals (IONS). These companies are all part of the "biotechnology" industry.
Halozyme Therapeutics vs.
Halozyme Therapeutics (NASDAQ:HALO) and Biogen (NASDAQ:BIIB) are both medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their media sentiment, risk, valuation, profitability, community ranking, analyst recommendations, dividends, earnings and institutional ownership.
Halozyme Therapeutics has a net margin of 43.74% compared to Biogen's net margin of 16.87%. Halozyme Therapeutics' return on equity of 157.78% beat Biogen's return on equity.
Biogen received 1295 more outperform votes than Halozyme Therapeutics when rated by MarketBeat users. Likewise, 71.28% of users gave Biogen an outperform vote while only 69.06% of users gave Halozyme Therapeutics an outperform vote.
97.8% of Halozyme Therapeutics shares are owned by institutional investors. Comparatively, 87.9% of Biogen shares are owned by institutional investors. 2.4% of Halozyme Therapeutics shares are owned by insiders. Comparatively, 0.2% of Biogen shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.
Halozyme Therapeutics has a beta of 1.26, suggesting that its stock price is 26% more volatile than the S&P 500. Comparatively, Biogen has a beta of 0.12, suggesting that its stock price is 88% less volatile than the S&P 500.
Halozyme Therapeutics currently has a consensus target price of $61.90, indicating a potential upside of 15.16%. Biogen has a consensus target price of $191.30, indicating a potential upside of 51.46%. Given Biogen's stronger consensus rating and higher possible upside, analysts clearly believe Biogen is more favorable than Halozyme Therapeutics.
Biogen has higher revenue and earnings than Halozyme Therapeutics. Biogen is trading at a lower price-to-earnings ratio than Halozyme Therapeutics, indicating that it is currently the more affordable of the two stocks.
In the previous week, Biogen had 17 more articles in the media than Halozyme Therapeutics. MarketBeat recorded 29 mentions for Biogen and 12 mentions for Halozyme Therapeutics. Biogen's average media sentiment score of 1.34 beat Halozyme Therapeutics' score of 0.86 indicating that Biogen is being referred to more favorably in the news media.
Summary
Biogen beats Halozyme Therapeutics on 10 of the 18 factors compared between the two stocks.
Get Halozyme Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for HALO and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip ChartMedia Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart
Halozyme Therapeutics Competitors List
Related Companies and Tools
This page (NASDAQ:HALO) was last updated on 5/23/2025 by MarketBeat.com Staff